Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation Affibody molecule with a fundamentally reengineered scaffold

Journal of Nuclear Medicine

Volumn 51, Issue 7, 2010, Pages 1131-1138

  Ahlgren, Sara ^a   Orlova, Anna ^a,b   Wållberg, Helena ^b   Hansson, Monika ^b   Sandström, Mattias ^c   Lewsley, Richard ^d   Wennborg, Anders ^b   Abrahmsén, Lars ^b   Tolmachev, Vladimir ^a,b   Feldwisch, Joachim ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d UK   (United Kingdom)

Author keywords

Affibody molecule; Molecular imaging; Peptides; Radiopharmaceuticals; Reengineered scaffold

Indexed keywords

ABY 025 IN 111; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MOLECULAR SCAFFOLD; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ABY 025; ABY-025; AMINO ACID; DIAGNOSTIC AGENT; HER2 PROTEIN, HUMAN; INDIUM; PEPTIDE FRAGMENT; STAPHYLOCOCCUS PROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VIVO STUDY; ISOTOPE LABELING; MACACA; MELTING POINT; MOLECULAR IMAGING; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PEPTIDE SYNTHESIS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RADIOACTIVITY; RAT; SCINTILLATION CAMERA; TUMOR; TUMOR MODEL; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOCHEMISTRY; METABOLISM; MOLECULAR GENETICS; SCINTISCANNING; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA CAMERAS; HUMANS; IMMUNOCHEMISTRY; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MACACA FASCICULARIS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; PEPTIDE FRAGMENTS; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; STAPHYLOCOCCAL PROTEIN A; TISSUE DISTRIBUTION;

EID: 77954963897     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.073346     Document Type: Article

References (33)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341-354.
2. Murphy CG, Modi S. HER2 breast cancer therapies: a review. Biologics. 2009;3:289-301.
3. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. (Pubitemid 350232263)
4. Molina R, Barak V, van Dalen A. et al. Tumor markers in breast cancer: European Group on Tumor Markers recommendations. Tumour Biol. 2005;26:281-293.
5. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552-556.
6. Kenanova V, Wu AM. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv. 2006;3:53-70.
7. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
8. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8:2861-2871.
9. Nord K, Nilsson J, Nilsson B, Uhlén M, Nygren P-Å. A combinatorial library of an α-helical bacterial receptor domain. Protein Eng. 1995;8:601-608.
10. Tolmachev V, Orlova A, Nilsson FY, et al. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555-568. (Pubitemid 46524679)
11. Orlova A, Magnusson M, Eriksson T, et al. Tumor imaging using a picomolar affinity HER2-binding Affibody molecule. Cancer Res. 2006;66:4339-4348.
12. 68Ga-labeled Affibody molecules. J Nucl Med. 2010;51:892-897.
13. Jansson B, Uhlén M, Nygren PA. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol Med Microbiol. 1998;20:69-78.
14. Orlova A, Tolmachev V, Pehrson R, et al. Synthetic Affibody molecules: a novel class of affinity ligands for molecular imaging of HER2 expressing malignant tumors. Cancer Res. 2007;67:2178-2189.
15. 18F-labeled Affibody molecules. J Nucl Med. 2009;50:1131-1139.
16. 124I-labeled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417-425.
17. 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med. 2009;50:1340-1348.
18. Mume E, Orlova A, Nilsson F, et al. Evaluation of (4-hydroxyphenyl) ethyl) maleimide for site-specific radiobromination of anti-HER2 affibody. Bioconjug Chem. 2005;16:1547-1555.
19. HER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47:846-853. (Pubitemid 46772889)
20. HER2:342, a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med. 2007;20:397-404.
21. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem. 2008;19:235-243.
22. Tolmachev V, Orlova A. Update on Affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotecnol. 2009;21:21-30.
23. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for Affibody molecules. J Mol Biol. 2010;398:232-247.
24. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
25. 99mTc-chelator engineering to improve tumor targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging. 2007;34:1843-1853.
26. 99mtc-labeled recombinant Affibody molecule, ZHER2: 2395, with C-terminally engineered cysteine. J Nucl Med. 2009;50:781-789.
27. 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm. 2008;23:435-442.
28. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
29. Lub-de Hooge MN, Kosterink JG, Perik PJ, et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99-106.
30. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51-58. (Pubitemid 40187381)
31. 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumor xenografts. Eur J Nucl Med Mol Imaging. 2009;36:81-93.
32. 89Zr-trastuzumab for HER2/neu ImmunoPET imaging. J Nucl Med. 2009;50:974-981.
33. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409-419.